AstraZeneca gets approval to import breast cancer treatment drug in India
The India approval is based on a global, head-to-head, randomised, open-label, registrational Phase III trial of DESTINY Breast 03.
The India approval is based on a global, head-to-head, randomised, open-label, registrational Phase III trial of DESTINY Breast 03.
CDRI spokesperson Sanjeev Yadav said, "Umifenovir was selected from 16 drugs suggested by CSIR after looking into the feasibility of synthesis using locally available chemicals at the peak of the pandemic. DCGI then gave permission for trials in June last year."
Oxford Institute vaccine Covishield which is being developed by Pune based Serum Institute and Bharat Biotech's Covaxin has been approved by Drug Controller General of India (DCGI) on Sunday for emergency use for immunisation against Covid-19.
